I think there is no clear guidelines for the treatment of concurrent RCC and CML. The determination of the CML status as primary or secondary is important.
I think after nephrectomy the determination of suspected getetic mutation is important before begining Sunitinib, sorafenib or Beva.
The combination of two target therapies is effective , but what is mandatory to register the genetic mutation during treatment.